Showing 581 - 600 results of 100,986 for search '(( 20 mm decrease ) OR ( 5 ((((step decrease) OR (we decrease))) OR (a decrease)) ))', query time: 1.63s Refine Results
  1. 581
  2. 582
  3. 583
  4. 584

    Cumulative release of Mn<sup>2+</sup> from MnO NPs over 24 hr after incubation in PBS pH 7.4 (dotted line), 20 mM citrate buffer pH 6.5 (dashed line), and 20 mM citrate buffer pH 5... by Celia Martinez de la Torre (9396180)

    Published 2020
    “…<p>Controlled release curves are shown for MnO NPs generated with the following temperature profiles: a) 5 min at 300°C with 20°C/min ramp, b) 5 min at 300°C with 10°C/min ramp, c) 15 min at 300°C with 20°C/min ramp, d) 15 min at 300°C with 10°C/min ramp, and e) 30 min at 300°C with 10°C/min ramp. …”
  5. 585

    Image5_Decreasing incidence and mortality of lung cancer in Hungary between 2011 and 2021 revealed by robust estimates reconciling multiple data sources.TIFF by Gabriella Gálffy (177759)

    Published 2024
    “…The COVID-19 pandemic resulted in a statistically significant decrease in lung cancer incidence, especially in the 50–59 age group (both sexes).…”
  6. 586

    The acetylation levels of histones at histone gene promoters decrease in cells with p300 knockdown. by Hongpeng He (348094)

    Published 2013
    “…<p>(A) p300 downregulation by siRNA resulted in cell accumulation in G1 phase. siRNA transfection was as described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0022088#pone-0022088-g002" target="_blank">Fig. 2A</a>. …”
  7. 587
  8. 588

    Nitrile in the Hole: Discovery of a Small Auxiliary Pocket in Neuronal Nitric Oxide Synthase Leading to the Development of Potent and Selective 2‑Aminoquinoline Inhibitors by Maris A. Cinelli (1309419)

    Published 2017
    “…We previously developed a class of membrane-permeable 2-aminoquinoline inhibitors and later rearranged the scaffold to decrease off-target binding. …”
  9. 589
  10. 590
  11. 591
  12. 592
  13. 593

    Uptake and Population-Level Impact of Expedited Partner Therapy (EPT) on <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i>: The Washington State Community-Level Randomi... by Matthew R. Golden (136790)

    Published 2015
    “…We conducted a stepped-wedge, community-level randomized trial to determine whether a public health intervention promoting EPT could increase its use and decrease chlamydia test positivity and gonorrhea incidence in women.…”
  14. 594
  15. 595
  16. 596

    Image4_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
  17. 597

    Image2_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
  18. 598

    Image6_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
  19. 599

    Image1_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
  20. 600

    Image3_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”